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NAN-190 potentiates the circadian response to light and speeds
re-entrainment to advanced light cycles
Eileen J Kessler1, Jeffrey Sprouse2, and Mary E Harrington1,*
1Neuroscience Program, Smith College, Northampton MA 01063
2Lundbeck Research USA, Paramus NJ 07652

Abstract
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Health problems can arise from de-synchrony between the external environment and the endogenous
circadian rhythm, yet the circadian system is not able to quickly adjust to large, abrupt changes in
the external daily cycle. In this study, we investigated the ability of NAN-190 to potentiate the
circadian rhythm response to light as measured by phase of behavioral activity rhythms. NAN-190
(5 mg/kg, i.p.) was able to significantly potentiate the response to light both in dark-adapted and
entrained hamsters. Furthermore, NAN-190 was effective even when administered up to 6 hours
after light onset. Response to a light pulse was both greater in magnitude and involved fewer unstable
transient cycles. Finally, NAN-190 was able to speed re-entrainment to a 6 h advance of the light:
dark cycle by an average of 6 days when compared to vehicle-treated animals. This work suggests
that compounds like NAN-190 may hold great potential as a pharmaceutical treatment for jetlag,
shift work, and other circadian disorders.
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Circadian rhythms are endogenously generated rhythms that coordinate processes such as
hormone release, digestive enzyme secretion, and the sleep/wake cycle. In mammals, the major
pacemaker is located in the suprachiasmatic nucleus (SCN) in the brain, which uses
environmental cues to synchronize, or entrain, internal rhythms to the external surroundings
(Rusak and Zucker, 1979; Ralph et al., 1990). Jetlag occurs when internal circadian rhythms
become desynchronized from the external time. In humans, this desynchronization results in
acute negative effects such as lowered performance levels on the job, difficulty sleeping at the
appropriate times, and gastrointestinal problems. If frequent or prolonged, circadian
desynchrony may be associated with more chronic health problems in people such as increased
risk of breast cancer, cardiovascular disease, reproductive difficulties and peptic ulcers
(Knutsson, 2003; Megdal et al., 2005). Studies using laboratory animals even link jetlag with
increased rate of tumor growth and increased mortality in aged mice (Davidson et al., 2006;
Filipski et al., 2004). Given the detrimental effects, studies have investigated several different
methods to reduce circadian desynchrony. Melatonin, exposure to bright light, and gradual
shifting of the sleep/wake cycle prior to jet travel in varying combinations have all been shown
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to speed re-entrainment in studies with humans (Eastman et al., 2005; Revell and Eastman,
2005; Sharkey and Eastman, 2001); however none of these methods are optimal, being
inconvenient and of limited effectiveness.
The serotonergic pathway from the raphe nucleus to the SCN may be a good target for jetlag
drug development. The effects of serotonin may be partially mediated by the 5HT1A receptor,
which is expressed as a post-synaptic receptor in the SCN and as both a post-synaptic and an
autoreceptor in the raphe nucleus. Serotonin (5HT) itself and synthetic agonists are able to
phase shift the circadian rhythm during the subjective day and attenuate light-induced phase
shifting during the subjective night in hamsters (Bobrzynska et al., 1996; Gannon and Millan,
2006; Horikawa et al., 2000; Rea et al., 1994; Tominaga et al., 1992). Furthermore, there have
been several reports of 5HT1A antagonists potentiating the phase advance to light, suggesting
that serotonergic tone on this receptor normally provides an inhibitory input to the SCN
(Gannon, 2003; Gannon and Millan, 2006; Rea et al., 1995; Lall and Harrington, 2006).
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In this study, we investigated the properties of NAN-190 as a pharmacological treatment for
circadian desynchrony. NAN-190 acts at the 5HT1A receptor, activating autoreceptors and
functionally antagonizing post-synaptic receptors (Claustre et al., 1991; Ryldelek-Fitzgerald
et al., 1990). NAN-190 has previously been shown to potentiate phase shifts to light (Lall and
Harrington, 2006; Rea et al., 1995). We tested NAN-190 in a series of experiments designed
to evaluate the robustness of its potentiating abilities with different pre-treatments, different
light pulse lengths, and different administration times with respect to the light. Finally, we
evaluated its ability to speed re-entrainment to a shifted light: dark cycle as occurs in jetlag.

Materials and Methods
General Methods
Animals—Male Syrian hamsters were purchased from Charles River at 3 to 4 weeks of age
and housed in translucent cages with wheels and ad lib access to food and water. They were
stably entrained to a 14:10 light dark: cycle prior to the start of any experiment. Animals were
randomly assigned to treatment groups. No animal received more than a total of 6 drug
injections over the course of all 5 experiments. Animals were re-entrained to a light: dark cycle
for a minimum of 10 days between experiments. Dim red light was less than 15 lux. Light
pulses were administered either at circadian time (CT) 19 or zeitgeber time (ZT) 19 using 40
watt fluorescent bulbs (Sylvania, F40/DSGN50). Circadian time 12 is defined as the time of
activity onset, and zeitgeber time 12 is defined as the onset of darkness in the light:dark (LD)
cycle.
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Data analysis and recording—Each hamster was housed with a running wheel equipped
with a magnet and switch; running wheel activity was recorded and compiled into actograms
by Clocklab software (Actimetrics, Evanston, IL). Daily activity onsets were determined using
Clocklab, which calculates activity onsets by fitting each day's activity to a template of 6 h of
inactivity followed by 6 h of activity. Onsets were edited by hand or omitted when necessary,
such as when the software selected an onset that was not at the start of a significant bout of
activity or data were missing due to equipment failure. Phase shifts were calculated using linear
regression lines fit to the 7 onsets pretreatment and 7 onsets post-treatment, omitting the three
days immediately post treatment in order to avoid transient cycles and allow the circadian
rhythm to reach a steady state. Each regression line was used to predict an activity onset for
the day after treatment; the difference between these two predictions was the phase shift.
Rate of re-entrainment was determined by examining the number of days needed to achieve a
steady state after a shift of the light: dark cycle. A regression line was fit to the activity onsets
of the last 5 days of stable entrainment 3 weeks post-treatment. This line was then extended
Neuroscience. Author manuscript; available in PMC 2009 July 17.
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back to the time of the LD shift and the number of days with onsets not yet on the regression
line was summed.
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In order to examine transient cycles, the cycles which occur during the period in which the
circadian clock is desynchronized from the environment before reaching a new steady state,
we compared first day post-treatment phase changes with final phase changes for all phase
shifting experiments with entrained animals. The times of activity onset for four days prior to
the day of treatment were averaged; the average was then subtracted from the time of activity
onset on first day post-treatment onset in order to determine the initial phase shift. This phase
shift was then compared to the final phase shift determined by the regression line method
described above.
Statistical analysis was performed using the SPSS 14.0 statistical package. All tests were run
with an alpha level of .05. Data were examined for outliers (defined as more than two standard
deviations from the mean), which were then omitted from further analyses (2 cases each in
Expt 1 and 2). Groups were compared with either t-tests or ANOVA, using Bonferroni's posthoc analysis or Tukey's HSD for multiple comparisons.
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Drugs and routes of administration—NAN-190 (Sigma) was dissolved in 50% DMSO
and administered via intraperitoneal (i.p.) injection at a 5 mg/kg dose. Vehicle injections
consisted of 50% DMSO solution only. All injection volumes were approximately 0.5 ml and
calculated based on the animal's weight as measured 2-5 days prior to treatment.

Experiment 1: Constant dark pretreatment
Methods
All hamsters (n=23) had been in constant darkness for more than 30 days at the time of
treatment. On the day before treatment, activity records were examined and the projected
activity onset calculated from a line fit to the past 6 days' onsets. Each animal's circadian period,
or amount of time for one complete circadian cycle, was used to calculate its circadian time
(CT) 19, 7 h after CT 12. CT 12 was defined as the time of the animal's activity onset. On
treatment day, hamsters received injections 45 m before their projected CT 19 under dim red
light. At each animal's individual CT 19, it was transported under dim red light in its cage to
a separate room to receive a 5 min light pulse (approximately 3,000 lux). A clean, empty cage
lid was placed over the top of the cage during the light pulse. At the end of the light pulse, the
animal was transported back to the home cage room under dim red light. Activity was
monitored for 10 days in constant darkness following the treatment.
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Results
Our results confirmed prior studies indicating Nan-190 potentiated light-induced shifts when
hamsters were housed in constant dark. Hamsters receiving NAN-190 showed a significantly
greater shift to light when compared to the controls (NAN-190: 4.54 ± 1.45 h; control: 2.77 h
± 0.90 h), t(21) = 2.64; p < .05). The results from this experiment are compared to those from
Experiment 2 in Figure 1, and actograms showing two individual hamsters responses are shown
in Figure 2.

Experiment 2: Entrainment pretreatment
Methods
Animals (n=18) were entrained to a 14:10 light dark cycle for 3 weeks; all experimental animals
displayed stable entrainment prior to receiving treatment. On the day of treatment, lights were
allowed to go off at the normal time, after which they remained off until the end of data
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collection (Aschoff, 1965). Treatments were given under dim red light. Nine animals received
NAN-190 and 9 received vehicle injections of 50% DSMO. Animals received injections
approximately 45 m before a 5 m light pulse at ZT 19 (approximately 2200 lux). The light
source was the same bulb type as used in experiment 1 (Sylvania, F40/DSGN50) but four bulbs
were mounted in a rack that could be placed in front of the animal cages, allowing equivalent
light exposure to hamsters regardless of where theyir cage was positioned on the rack. Animals
remained in their home cages in the housing room for the light pulse. After the light pulse,
animals were left in constant dark for 10 days, after which they were re-entrained.
Results
This experiment demonstrated that Nan-190 is able to potentiate shifts to light even in entrained
hamsters. The NAN-190-treated group showed a significantly larger phase shift (4.27 ± 0.92
h) than the vehicle-treated group (1.62 ± 0.28 h), t(13) = 8.23, p< .001). The effect was
comparable to that observed in hamsters housed in constant darkness prior to the light pulse,
as is shown in Figure 1. All our further experiments were conducted using hamsters entrained
to a LD cycle prior to treatment.

Experiment 3: Different durations of light
Methods
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Animals (n=38) were stably entrained to a 14:10 light: dark cycle at least 10 days before
treatment. On the day of treatment, the lights went off at the normal time, after which they
remained off until the end of data collection. Treatments were given under dim red light.
Animals received injections approximately 45 m before ZT 19, at which time the light pulse
commenced. Half the animals were removed from the home cage room by wheeling their
housing cage rack into a dark hallway, where they remained after 15 m of light. The remainder
of the animals received an additional 15 m of light during that time, for a total light pulse of
30 m duration. At the end of the light pulse, all animals returned to the housing cage room
under dim red light. Activity was recorded in constant dark for 10 days.
Results
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This experiment indicated that the effect of NAN-190 was more robust when combined with
a 30 min light pulse as vs. a 15 min pulse (data shown in Table 1). NAN-190 significantly
potentiated the advance to light in both the 15 and the 30 m light pulse conditions (t(16) = 2.41;
p < .05 and t(18) = 5.86; p < .01, respectively). The two vehicle-treated groups did not
significantly differ from each other (t(17)=.299; p > .05), but NAN-190 was able to significantly
potentiate the response to a 30 m light pulse (138.34%) more than to a 15 m light pulse (47.27%)
(F(3, 34) = 18.201, p < .01; Tukey's HSD reveals NAN-190 + 30 m light pulse significantly
different from all other groups.) Based on these results, all subsequent experiments used a 30
m light pulse.

Experiment 4: Drug administration time-course
Methods
Three trials of a drug-administration time-course experiment were run. All animals (n=44)
were stably entrained to a 14:10 light dark cycle for at least 2 weeks before treatment. Animals
were randomly assigned to receive either NAN-190 or vehicle injection at one of four time
points: either 45 m prior to the start of the light pulse; 30 m, 1 h, or 1.5 h after the start of the
light pulse. In the second trial, animals (n=40) were randomly assigned to receive either
NAN-190 or vehicle injection 1.5 h, 3 h, 4.5 h, or 6 h after the start of the light pulse. In the
third trial, NAN-190 or vehicle injections were administered without light, at 45 m before ZT
19 (ZT 18.25), or 1.5 h, 3 h, 4.5 h, or 6 h after ZT 19 (ZT 20.5, 22, 23.5 or 1, respectively).
Neuroscience. Author manuscript; available in PMC 2009 July 17.
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On the day of treatment, the lights went off at the normal time, after which they remained off
until the end of data collection. Treatments were given under dim red light. Animals received
a 30 m light pulse at ZT 19. At the predetermined injection times, hamsters received either the
NAN-190 or vehicle injections under dim red light. At the end of the light pulse, the lights
were turned off and remained off for 10 days for data collection.
Results
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Surprisingly, NAN-190 was able to significantly potentiate the response to light for each
treatment time, even when the drug was administered as long as 6 h following the light pulse.
This can be seen in Figure 3, comparing the vehicle treated light-exposed hamsters (open bars)
with the NAN-190 treated light exposed hamsters (solid filled bars). No significant differences
were found between the drug-treated animals which received light (F(6, 39) = 2.33, p = .05),
regardless of time of drug administration. The Student's t test was used for planned comparisons
between vehicle- and drug-treated groups at each time point with and without light. For the
animals receiving light pulses, only one significant difference was found between vehicletreated animals at the different time points (F(6,30)=2.68; p < .05); Bonferroni's post hoc
analysis revealed that hamsters treated with vehicle at 30 minutes shifted 1.04 h less than those
treated at 3 h (p = .046). No other groups significantly differed from each other. NAN-190
caused small but significant shifts when administered without a light pulse at ZT 22 (t(3) =
-5.26, p<.05), ZT 23.5 (t(3) = -24.03, p<.01) and ZT 1(t(3) = -4.47, p <.05). This experiment
indicated the timing of NAN-190 is much more flexible than has been reported for other
compounds that influence the light-input pathways, and suggested this compound might have
robust effects on re-entrainment to a shifted LD cycle.

Experiment 5: Re-entrainment to a 6 h advance of the LD cycle
Methods
Animals were re-entrained to a 14:10 light cycle (n=44). Once stable entrainment had been
achieved, the light cycle was advanced six h by means of a short night (Day 1). On Day 1 of
the light cycle advance, animals received an injection of either NAN-190 or vehicle either 45
m before the new lights-on time or 1 h after it. They were then left, undisturbed, to re-entrain
to the new light cycle. To test if drug treatment plus one day of light exposure was sufficient
for re-entrainment, a second group of animals (n= 20) received one full day of the advanced
light cycle and either an injection of NAN-190 or vehicle 1 h after the start of the new light
cycle. They were then placed in constant dark for 10 days.
Results
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Figure 4 shows actograms from representative animals following the LD shift. The control
animal required 10 days to re-entrain to the shifted LD cycle, whereas the NAN-190 treated
animal was re-entrained the next day (see Figure 4). Actograms from all animals in this
experiment are represented in Figure 5 where we plot the time of activity onset for each animal
on each day of the experiment. It is clear from Figure 5 that the individual results shown in
Figure 4 were commonly observed. Overall, NAN-190 significantly reduced the number of
days needed to re-entrain to a 6 h shift of the light: dark cycle (F(3, 36) = 31.64, p<.01).
Bonferroni's post hoc analysis revealed that both groups of NAN-190- treated animals reentrained significantly faster than the vehicle- treated controls but that there was no significant
effect of time of drug administration (NAN-190 45 m pretreatment: 2.4 ± 2.5 days; NAN-190
1 h post-light 1.1 ± 1.3 days; vehicle 45 m pretreatment: 7.4 ± 1.8 days; vehicle 1 h post-light:
7.8 ± 1.9). The hamsters treated with only one day of the shifted LD cycle showed results
supporting the conclusion that much of the shift was accomplished within one day of the 6 h
LD shift. NAN-190 treated animals shifted an average of 4.5 h whereas vehicle treated animals
only shifted 2.2 h (t(18) = -4.40, p<.01).
Neuroscience. Author manuscript; available in PMC 2009 July 17.
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We noted throughout these experiments that the animals treated with NAN-190 showed few
if any transient cycles. To quantify this, all phase shifts from Experiments 2-4 were examined
for duration of transient cycles by comparing the percent of the final phase shift achieved on
the day immediately following treatment. Percentages for each treatment group are presented
in Table 1. Overall, NAN-190 treated animals achieved between 80 and 100 percent of their
final phase shift, whereas vehicle treated animals achieved between 37 and 53 percent of their
final shift by the first day after treatment. We show in Figure 6 that animals treated with
NAN-190 achieved significantly higher percentages of their final phase shifts by the first day
following treatment than did vehicle treated animals in all conditions across experiments 2-4.
Vehicle-treated animals under different conditions did not differ in the percentage achieved.

Discussion
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Our studies indicate that NAN-190 consistently potentiated circadian clock resetting following
light exposure under various conditions. NAN-190-treated groups showed an enhanced
response to light after prolonged exposure to constant dark or directly from entrainment.
NAN-190's potentiating abilities may be sensitive to the duration of light exposure; however,
this response may saturate around 30 m of light. Pretreatment was effective but not necessary
since administration as much as 6 h following the start of the light pulse continued to be as
effective. Most importantly, NAN-190 increased the rate of adjustment to a new phase. Our
results demonstrate that following a 6 h advance of the light: dark (LD) cycle, an amount noted
to induce maximal internal desynchrony (Leise and Siegelmann, 2006), the time needed to
adjust to the new cycle diminished from 7-8 to 1-2 days as a result of a single drug
administration.
As with the present findings, earlier reports noted that compounds acting at the 5HT1A receptor
potentiate the response to light (Gannon, 2003; Gannon and Millan, 2006; Moriya et al.,
1998; Rea et al. 1995; Lall and Harrington, 2006). These studies, however, uniformly employed
an experimental design in which animals were housed in constant darkness for several days
prior to treatment. Our experiments demonstrate that NAN-190 not only enhances lightinduced shifts under these conditions but retains its potentiating effects when administered to
hamsters currently entrained to a fixed LD cycle. This is an important distinction as it more
readily allows extrapolation to everyday living (albeit in a nocturnal species). Shifts in the
laboratory LD cycle can then be viewed as shifts in the rest-activity cycles that occur in
transmeridian travel or as a result of lifestyle choices.
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Transient cycles are those that are generated during the period that the circadian clock is
desynchronized from the environment before reaching its re-synchronized steady state
(Pittendrigh et al., 1958). Following a phase shift, peripheral oscillators in various internal
organs also become desynchronized, a condition thought to underlie the symptoms of jet-lag
(Yamazaki et al., 2000). On a human scale, the transient cycles represent the days of gradual
re-synchronization, in which physical symptoms such as tiredness and gastrointestinal upset
occur (Revell and Eastman, 2005). Sildenafil, a potent and selective inhibitor of
phosphodiesterase 5, has recently been shown to increase the rate of re-entrainment of hamsters
following a 6 h advance of the LD cycle, decreasing the number of days required for reentrainment by up to 50% (Agostino et al., 2007). However, sildenafil did not appear to alter
the number of transient cycles following a single light pulse-induced phase shift, whereas in
our experiments NAN-190 sped the rate of resetting such that fewer transient cycles occurred.
The latter was observed both in the single light pulse and re-entrainment paradigms; earlier
studies reported similar abrupt phase shifts with NAN-190 (Rea et al., 1995) and with BMY
7378 and S15535, compounds that also act as 5HT1A partial agonists (Gannon, 2003).
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While we have demonstrated the ability of NAN-190 to potentiate the light-induced advance
in wheel-running activity, we do not know whether the compound would yield potentiated
shifts in peripheral oscillators as they may occur in (e.g.) the liver or lungs. MKC-242, a
selective 5-HT1A partial agonist, is able to potentiate light-induced shifts in mice (Moriya et
al., 1998; Takahashi et al., 2002); consequently, there is good reason to believe NAN-190 will
also, offering the possibility of measuring similar effects on peripheral oscillators using
luciferase reporter animals (e.g. Yoo et al., 2004). The relationship between the central and the
peripheral oscillators may be just as important to human functioning as the relationship which
ties SCN timekeeping to the solar day; it may also be directly related to the symptoms of shift
lag during transient cycles (Shibata, 2007; Yamazaki et al., 2000).
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NAN-190 has high affinity for 5HT1A receptor sites, where it acts as a partial agonist (Claustre
et al., 1991; Rydelek-Fitzgerald et al., 1990). On raphe neurons, limited activation of cell body
autoreceptors is sufficient to diminish firing frequency, as a result of extensive receptor reserve
(Fornal et al., 1994). On postsynaptic sites where receptor reserve might be less extensive, the
same degree of partial agonist receptor activation can antagonize the action of more robust
agonists; this has been shown with 8-OH-DPAT (Claustre et al., 1991). The net effect of
diminished cell firing (and consequently diminished 5-HT release) and functional postsynaptic
receptor antagonism is a reduction in serotonergic tone to the SCN. The same is true for
MKC-242, although this compound may display greater agonist properties in the agonistpartial agonist-antagonist continuum (Matsuda et al., 1995). Interestingly, both compounds
also share the ability to block alpha-1 adrenergic receptors; at the level of the raphe nuclei, this
action too can reduce cell firing by removing excitatory noradrengic tone (Baraban and
Aghajanian, 1980). Removing the serotonergic tone from the SCN may account for the greater
responsiveness to light.
NAN-190 is also able to induce small phase advances without light in the late night or early
morning, but not earlier, at ZT 19. However, the small shifts (approximately 1 h) seen with
NAN-190 alone are not sufficient to explain the large shifts (4.5-6 h) seen when NAN-190
administration follows a light pulse, either by themselves or through additive phase shifts.
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NAN-190's cellular mechanisms are as of yet unclear. MKC-242 has been shown to prolong
the light-induced increases in both per1 and per2 mRNA (Takahashi et al., 2002), which
normally decay within a few hours (Best et al., 1999; Khammanivong and Nelson, 2000). Since
both per mRNA and Per protein levels are correlated with behavioral phase shifting (Best et
al., 1999; Masubuchi et al., 2005), it is possible that the greater phase advance to light observed
with MKC-242 and NAN-190 may be due to their extended elevation of per, and thus Per
protein. Such might be accomplished by allowing enhanced Per production from the lightinduced per mRNA or by affecting the stability of Per protein (which is known to alter phaseshift magnitude) (Gallego et al., 2006; Jakubcakova et al., 2007; Lee et al., 2007; Masubuchi
et al., 2005). Naturally, there are many other potential targets in addition to per and Per protein
and at this point in time, they cannot be ruled out. However, it is clear that the compound is
not altering cellular events coincident with light; NAN-190 is effective when given between 1
and 6 hours after the light pulse, strongly supporting the idea that the interaction occurs later
in the intracellular cascade.
Of the two short light pulse durations employed, NAN-190 yielded greater potentiation to the
longer pulse with average phase advances approximately 4 hours in length. Earlier studies
suggested that the hamster circadian system is normally only able to phase shift a maximum
of approximately 2 hours per day (Nelson and Takahashi, 1999), an idea supported by our
vehicle-treated controls. In other words, after a certain quantity of light, achieved either through
intensity or duration, the system saturates and is unable to shift more (Khammanivong and
Nelson, 2001; Nelson and Takahashi, 1999). The saturation point may occur around 30 m of
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light with NAN-190; a full day of a shifted light:dark cycle did not yield a larger average shift
than the 30 m pulse did.
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Finally, NAN-190 or similar compounds may have clinical application. As noted earlier,
current jetlag treatments consist of exposure to light pulses, shifting the sleep-wake cycle
gradually prior to travel, and taking melatonin before the altered bedtime (Eastman et al.,
2005; Revell and Eastman, 2005; Sharkey and Eastman, 2001). Each of these methods is less
than optimally effective and undoubtedly inconvenient for the subject. NAN-190 (or
compounds like it) offers the promise of much quicker and more effective clock resetting, with
the convenience of one-time dosing on the day of the shifted schedule. Proof might come by
selecting agents for study that are currently marketed. For example, buspirone, or Buspar, has
been shown to accelerate the rate of re-entrainment in phase-advanced hamsters (Tominaga et
al., 1992). Our results raise the possibility that this anxiolytic/antidepressant and other 5HT1A
receptor partial agonists might be an untapped source for the relief of jet-lag and associated
circadian rhythm disorders.
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Figure 1.

Mean phase shift for light alone, vehicle (V)- and drug (N)- treated animals both from constant
dark and from entrainment. NAN-190 treated animals show a significantly greater phase shift
than controls in both paradigms. Asterisks indicate significance (p < .05); error bars represent
SEM.
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Figure 2.
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Representative activity records from two animals from experiment 1. Bull's-eye indicates time
of treatment A: An animal that received the light pulse only, showing a moderate shift with
three days of transient cycles before steady state is achieved. B: A NAN-190 treated animal,
showing a large shift with no transient cycles.
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Figure 3.
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An administration time course showing the mean phase shifts of animals treated with vehicle
(white bars) or NAN-190 (black bars) 45 minutes before the light pulse onset or 30 minutes,
1, 1.5, 3, 4.5, or 6 hours after, with the arrow indicating relative placement of the light pulse.
NAN-190 was able to significantly potentiate the response to light at all time points (indicated
by asterisks.) Gray and striped bars indicate vehicle-and NAN-190-treated (respectively)
animals with no light exposure. NAN-190 was able to induce a small, significant shift on its
own when administered at later time points (indicated by #; p< .05). Error bars represent SEM.
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Figure 4.
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Representative activity records from two animals during the re-entrainment period of
experiment 5. Bull's-eye indicates time of treatment. Both animals received injections 45 m
before the new lights on. A: A vehicle treated animal, which took 10 days to re-entrain. B: A
NAN-190 treated animal, which was re-entrained the next day. Again, the NAN-190 treated
animal displays many fewer transient cycles and achieves a steady entrainment significantly
faster than the vehicle treated animal.
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Figure 5.

Plots of the onsets of vehicle- and drug-treated animals during experiment 5. Each point
represents the onset of 1 day; successive days are plotted below each other. A, C: Vehicletreated animals at 45 minutes before and 60 minutes after new lights on. B, D: NAN-190treated animals 45 minutes before and 60 minutes after new lights on. Vehicle treated animals
show a more gradual curve to re-entrain to the new light cycle than do drug-treated animals,
regardless of time of drug administration. Shading indicates time when the lights are on.
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Figure 6.

Transient cycles as measured by the percent of the final shift achieved on day 1 following
treatment for vehicle- (V) and NAN-190-treated (N) animals in the experiments 2
(“Entrainment”), 3 (“Light pulses”), and 4 (“Time course”). NAN-190 treated animals
consistently achieve twice as much of their shift as did vehicle treated animals. Error bars
indicate SEM. Asterisks indicate statistical significance (p< .05).
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